Pentoxifylline in prevention of amphotericin-induced nephrotoxicity and electrolytes imbalances

Pentoxifylline in prevention of amphotericin-induced nephrotoxicity and electrolytes imbalances in patients hospitalized in university affiliated hospital, Sayyed-o-Shohada, 2016-2017: a randomized, double blinded, placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016071328901N1

Enrollment

Registered

2016-10-06

Start date

2016-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fungal infections. Unspecified mycosis

Interventions

Intervention 1: Control group: Placebo 800 mg/day, oral, administered concomitantly with Amphotericin (from the beginning till the final dose of Amphotericin). Intervention 2: Intervention group: Pen

Treatment - Drugs

Control group: Placebo 800 mg/day, oral, administered concomitantly with Amphotericin (from the beginning till the final dose of Amphotericin)

Intervention group: Pentoxiphylline 800 mg/day, oral, administered concomitantly with Amphotericin (from the beginning till the final dose of Amphotericin)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Adult patients (over age 18) with malignancy or fever/neuropenia who receive conventional form of Amphotericin for at least one week; patients with CrCl > 60 mL/min. Exclusion criteria: Patients who received Amphotericin during two weeks before hospitalization; Patients with mucositis, or any other GI complication who can not tolerate Pentoxiphylline administration; History of reaction to Pentoxiphylline or other Xanthines; Renal insufficiency or electrolyte imbalances at the study beginning.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nephrotoxicity or Electrolyte imbalances. Timepoint: From day 1 to day 7 during treatment. Method of measurement: Renal indices and Electrolytes.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShirinsadat Badri

Isfahan University of Medical Sciences

badri@pharm.mui.ac.ir+98 31 3792 7068

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026